SCHEMBL7602340

SCHEMBL7602340

Cc1cc2c(cc1C)N(CCNC(=O)C(F)F)C(=O)C1(CCC1)O2

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
REN P00797 6/20 0.41
NR3C2 P08235 1/20 0.34
LMNA P02545 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7602330 0.85 REN (0.44) RENNR3C2
SCHEMBL7606455 0.85 REN (0.45) RENNR3C2THRB
SCHEMBL7602333 0.84 REN (0.48) REN
SCHEMBL7601630 0.80 REN (0.47) REN
SCHEMBL2242509 0.79 REN (0.32) REN
SCHEMBL7641182 0.77 NR3C2 (0.35) RENNR3C2
Hydrochloric Acid SCHEMBL2243572 0.76 SLC6A2 (0.33) REN
SCHEMBL2720486 0.76 REN (0.33) REN
SCHEMBL12354365 0.73 KAT7 (0.33) REN
SCHEMBL12353060 0.72 ALDH1A1 (0.40) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US disclosed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 REN 1/4885NR3C2 22/4885LMNA 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.